Lower than a yr after its final financing, Click on Therapeutics raised $52 million to develop its portfolio of software-based remedies. The New York-based startup just lately raised a sequence B spherical led by H.I.G. BioHealth Companions and Accelmed Companions II. Sanofi, an early investor within the firm, additionally participated in its most up-to-date fundraise.
Click on plans to make use of the funds to develop and commercialize extra of its digital therapeutics, and construct out its platform to foretell the optimum course of remedy for every affected person.
The corporate’s CEO and co-founder, David Benshoof Klein, described Click on’s sequence B spherical as an “vital milestone.”
“We’re excited to welcome our new buyers and deepen {our relationships} with current buyers, all of whom share our imaginative and prescient of a brand new healthcare panorama during which prescription digital therapeutics play a distinguished function alongside conventional pharmacological remedies,” he mentioned in a information launch.
To date, the startup has introduced one app-based remedy to market: a digital smoking cessation program it developed with PBM Magellan Well being.
It’s additionally launching a pivotal trial of a digital therapeutic for melancholy that it’s growing together with Otsuka Pharmaceutical. The businesses are enrolling 540 folks for the 12-week trial, to judge the security and efficacy of the digital therapeutics in adults who’re taking antidepressants.
Click on has different tasks in its pipeline which might be within the earlier levels. Final yr, it struck a $500 million partnership with Boehringer Ingelheim to develop a digital therapeutic for schizophrenia. It’s additionally engaged on remedies for continual ache, cardiometabolic and autoimmune problems.
As a part of the funding spherical, H.I.G. BioHealth Managing Director Alex Zison and Accelmed Managing Companion Uri Geiger will be a part of Click on’s board of administrators.
Picture credit score: Getty Pictures, photo_chaz